Skip to content
approvedHormone Regulation

Protirelin

Also known as: TRH, Thyrotropin-Releasing Hormone, Thyrel TRH, Relefact TRH, Thypinone, Pyro-Glu-His-Pro-NH₂

Protirelin is the synthetic form of thyrotropin-releasing hormone (TRH), an endogenous tripeptide (pyroglutamyl-histidyl-proline amide) produced by the paraventricular nucleus of the hypothalamus. It is the smallest known biologically active peptide hormone and sits at the top of the hypothalamic-pituitary-thyroid (HPT) axis, stimulating TSH and prolactin release from the anterior pituitary. FDA-approved as a diagnostic agent for evaluating thyroid and pituitary function, the TRH stimulation test was once a cornerstone of thyroid diagnostics before being largely replaced by sensitive TSH assays. Protirelin also has investigational applications in neurodegenerative diseases, consciousness disorders, and depression.

3 cited references·5 researched benefits

Quick Answer

Protirelin is the synthetic form of thyrotropin-releasing hormone (TRH), the smallest known biologically active peptide hormone at just three amino acids. FDA-approved for thyroid function testing, the TRH stimulation test evaluates pituitary TSH reserve by measuring TSH response to an IV bolus. Though largely replaced by sensitive TSH assays for routine diagnostics, it remains valuable for distinguishing secondary from tertiary hypothyroidism and evaluating TSH-secreting adenomas.

Key Facts

Mechanism
Protirelin binds to TRH receptor type 1 (TRH-R1), a Gq-coupled GPCR expressed on thyrotrophs and lactotrophs in the anterior pituitary. Receptor activation triggers phospholipase C-mediated IP3 and DAG production, mobilizing intracellular calcium and activating protein kinase C, which stimulates exocytosis of pre-formed TSH and prolactin from secretory granules. TSH rises within 2-5 minutes and peaks at 20-30 minutes, while prolactin rises in parallel. TRH also has extensive extrahypothalamic distribution in the CNS, where it acts as a neuromodulator affecting arousal, locomotion, thermoregulation, and autonomic function through TRH-R1 and TRH-R2 receptors. Its rapid degradation by the pyroglutamyl peptidase II (TRH-DE) ectoenzyme at the median eminence provides exquisite temporal control of pituitary stimulation.
Research Status
approved
Half-Life
~5 minutes (plasma)
Molecular Formula
C₁₆H₂₂N₆O₄
Primary Use
Hormone Regulation
Table of Contents

Benefits

  • Diagnostic test for pituitary TSH reserve — the TRH stimulation test differentiates secondary (pituitary) from tertiary (hypothalamic) hypothyroidism based on TSH response patternstrong
  • Evaluates TSH-secreting pituitary adenomas — absence of TSH rise after TRH distinguishes autonomous TSH secretion (adenoma) from thyroid hormone resistancestrong
  • Assesses prolactin reserve and dynamics — useful in evaluating hyperprolactinemia etiology and pituitary stalk lesionsstrong
  • Investigational analeptic properties — TRH analogs improve arousal and consciousness in brain injury, potentially through brainstem activating system stimulationpreliminary
  • Potential neuroprotective agent — TRH and analogs show preclinical benefit in spinal cord injury, ALS models, and neurodegenerative conditions through anti-apoptotic and neuromodulatory effectspreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous bolus (TRH stimulation test)200-500 mcgSingle dose; TSH measured at 0, 15, 30, and 60 minutesStandard diagnostic dose is 200-500 mcg given as rapid IV bolus. Normal response: TSH rises ≥5 mU/L above baseline and peaks at 20-30 minutes. Blunted response suggests hyperthyroidism or autonomous TSH secretion. Exaggerated/delayed response suggests hypothalamic (tertiary) hypothyroidism.
Intravenous (research — consciousness disorders)0.5-2 mgSingle dose or repeated doses in research protocolsInvestigational use for evaluating TRH as an analeptic agent in traumatic brain injury and disorders of consciousness. Higher doses than diagnostic testing. Not FDA-approved for this indication.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Transient hypertension — blood pressure rise of 10-30 mmHg for 5-10 minutes after IV injection; use caution in patients with severe hypertensioncommon
  • Nausea and urge to urinate — the most characteristic side effects, occurring within seconds of injection and lasting 1-5 minutescommon
  • Flushing, lightheadedness, and metallic taste — transient sensory effects reported in 20-50% of patients receiving diagnostic dosescommon
  • Headache — reported in 5-15% of patients, usually mild and self-resolving within 30 minutescommon
  • Pituitary apoplexy — extremely rare but reported in patients with pre-existing pituitary macroadenomas; the sudden stimulation can cause hemorrhage into the adenomaserious

Frequently Asked Questions

Why is the TRH stimulation test rarely used today?
The TRH stimulation test was once essential for diagnosing hypothyroidism and hyperthyroidism when TSH assays were insensitive and could not reliably detect suppressed TSH levels. The development of third-generation sensitive TSH assays (capable of detecting TSH levels as low as 0.01-0.02 mU/L) in the 1990s made the TRH test unnecessary for routine thyroid diagnostics — a low sensitive TSH with high free T4 diagnoses hyperthyroidism, and a high TSH with low free T4 diagnoses primary hypothyroidism. The TRH test retains clinical utility only in niche situations: differentiating secondary from tertiary hypothyroidism, evaluating TSH-secreting adenomas, and research applications.
Is protirelin still commercially available?
Protirelin availability has become limited in many countries. In the United States, the branded product Thyrel TRH was discontinued by the manufacturer due to low demand, though some compounding pharmacies may prepare it. It remains available in Japan (where the TRH test is more commonly used), some European countries, and through specialized diagnostic laboratories. The declining availability reflects the reduced clinical demand since sensitive TSH assays replaced the TRH test for most thyroid diagnostics. When needed for rare diagnostic indications, clinicians may need to source protirelin through specialty suppliers.
What are the neurological applications of TRH?
TRH has extensive CNS distribution beyond the hypothalamus and functions as a neuromodulator affecting arousal, autonomic function, and neuroprotection. In clinical research, TRH and its analogs have shown: (1) analeptic (awakening) effects in consciousness disorders — IV protirelin can transiently improve arousal in brain-injured patients; (2) potential benefit in spinal cord injury — TRH analogs improved neurological outcomes in animal models; (3) antidepressant effects — intrathecal TRH produced rapid mood improvement in treatment-resistant depression; (4) ALS — TRH analogs briefly improved motor function in early trials but did not show sustained benefit. The ultra-short half-life of native TRH limits clinical utility, driving development of more stable TRH analogs.
How does TRH relate to depression?
TRH has been linked to depression through multiple mechanisms. Many depressed patients show a blunted TSH response to TRH (the "TRH test" abnormality), which was once proposed as a biological marker for depression. Direct injection of TRH into the spinal fluid produced rapid antidepressant effects in several small studies, suggesting TRH has mood-elevating properties independent of thyroid function. TRH modulates serotonergic and dopaminergic neurotransmission in mood-regulating brain regions. These observations contributed to the understanding that thyroid hormone augmentation (T3) can enhance antidepressant response, and TRH analogs with improved stability are being explored as potential novel antidepressants.

References

  1. 1
    Synthetic thyrotropin-releasing factor: a potent and specific stimulator of thyrotropin secretion(1970)PubMed ↗
  2. 2
    The TRH stimulation test: current status and future directions(1991)PubMed ↗
  3. 3
    Thyrotropin-releasing hormone and its analogs in neurodegenerative diseases(2008)PubMed ↗

Latest Research

Last updated: 2026-02-19